CN118139886A - 作为免疫刺激剂的激动性cd40抗体 - Google Patents

作为免疫刺激剂的激动性cd40抗体 Download PDF

Info

Publication number
CN118139886A
CN118139886A CN202280066589.8A CN202280066589A CN118139886A CN 118139886 A CN118139886 A CN 118139886A CN 202280066589 A CN202280066589 A CN 202280066589A CN 118139886 A CN118139886 A CN 118139886A
Authority
CN
China
Prior art keywords
antibody
cancer
fragment
region
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280066589.8A
Other languages
English (en)
Chinese (zh)
Inventor
S·费舍尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAB Discovery GmbH
Original Assignee
MAB Discovery GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAB Discovery GmbH filed Critical MAB Discovery GmbH
Publication of CN118139886A publication Critical patent/CN118139886A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280066589.8A 2021-10-01 2022-09-30 作为免疫刺激剂的激动性cd40抗体 Pending CN118139886A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21200496.4 2021-10-01
EP21200496 2021-10-01
PCT/EP2022/077270 WO2023052581A1 (en) 2021-10-01 2022-09-30 Agonistic cd40 antibodies as immune stimulatory agents

Publications (1)

Publication Number Publication Date
CN118139886A true CN118139886A (zh) 2024-06-04

Family

ID=78078007

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280066589.8A Pending CN118139886A (zh) 2021-10-01 2022-09-30 作为免疫刺激剂的激动性cd40抗体

Country Status (7)

Country Link
US (1) US20240392026A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408537A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538573A (cg-RX-API-DMAC7.html)
CN (1) CN118139886A (cg-RX-API-DMAC7.html)
AU (1) AU2022358474A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232917A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023052581A1 (cg-RX-API-DMAC7.html)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2019057792A1 (en) * 2017-09-19 2019-03-28 Mab Discovery Gmbh CD40 ANTIBODY AGONISTS

Also Published As

Publication number Publication date
US20240392026A1 (en) 2024-11-28
CA3232917A1 (en) 2023-04-06
AU2022358474A1 (en) 2024-03-28
JP2024538573A (ja) 2024-10-23
EP4408537A1 (en) 2024-08-07
WO2023052581A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
CN112088167B (zh) 特异性针对人类连接蛋白4的抗体
CN112424229B (zh) 结合cd137和ox40的抗体分子
EP3193931B1 (en) Neutralization of inhibitory pathways in lymphocytes
AU2014351308B2 (en) Compositions comprising anti-CEACAM1 and anti-PD antibodies for cancer therapy
JP7384835B2 (ja) Cd3に特異的な抗体及びその使用
RU2692248C2 (ru) Улучшенные способы лечения васкуляризированных злокачественных опухолей
TW202010756A (zh) 抗體分子
JP2018524300A (ja) 免疫応答を調節するための方法および抗体
KR20180102628A (ko) 면역조절제의 조합물에 의한 암의 치료
US20210380700A1 (en) De-adcc/cdc functions of antibodies and their applications
KR20210117277A (ko) 인간 넥틴-2에 특이적인 항체
CN117551197A (zh) 激动性cd40抗体
KR20210010486A (ko) 암의 치료
TW202313682A (zh) 抗icos抗體之用途
EP4346887A1 (en) C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
US20230365714A1 (en) Antibodies capable of binding to ror2 and bispecific antibodies binding to ror2 and cd3
US20240392026A1 (en) Agonistic cd40 antibodies as immune stimulatory agents
TWI790193B (zh) 調控免疫反應之方法及抗體
JP2024517985A (ja) 抗-CD300cモノクローナル抗体及びその癌の予防または治療用バイオマーカー
HK40110316A (en) Neutralization of inhibitory pathways in lymphocytes
EA045980B1 (ru) Антитела против рецептора полиовируса (pvr) и их применение
HK40046552A (en) Antibodies specific for cd3 and uses thereof
EA051733B1 (ru) Композиции, содержащие комбинацию анти-lag-3 антитела, ингибитора сигнального пути pd-1 и иммунотерапевтического средства

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination